A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)
收藏DataCite Commons2025-12-12 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012127/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.
提供机构：
Vivli
创建时间：
2025-12-11
